CG Oncology (CG Oncology) Pretax Margin % : -3,200.76% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. CG Oncology's Pre-Tax Income for the three months ended in Mar. 2024 was $-16.93 Mil. CG Oncology's Revenue for the three months ended in Mar. 2024 was $0.53 Mil. Therefore, CG Oncology's pretax margin for the quarter that ended in Mar. 2024 was -3,200.76%.

The historical rank and industry rank for CG Oncology's Pretax Margin % or its related term are showing as below:

CGON' s Pretax Margin % Range Over the Past 10 Years
Min: -23826.96 Med: -18556.54 Max: -123.95
Current: -6235.47

CGON's Pretax Margin % is ranked worse than
87.3% of 1024 companies
in the Biotechnology industry
Industry Median: -152.6 vs CGON: -6235.47

CG Oncology Pretax Margin % Historical Data

The historical data trend for CG Oncology's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Pretax Margin % Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Pretax Margin %

-123.95

-18,556.54

-23,826.96

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Pretax Margin %	Get a 7-Day Free Trial			-	-4,467.53	-	-1,611,600.00	-3,200.76

Competitive Comparison of CG Oncology's Pretax Margin %

For the Biotechnology subindustry, CG Oncology's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where CG Oncology's Pretax Margin % falls into.

CG Oncology Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

CG Oncology's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-48.607	/	0.204
	=	-23,826.96 %

CG Oncology's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-16.932	/	0.529
	=	-3,200.76 %

CG Oncology (NAS:CGON) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

CG Oncology Pretax Margin % Related Terms

Thank you for viewing the detailed overview of CG Oncology's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024